TemSujohn: Advanced Relief for Chronic Neuropathic Pain
Temsujohn
| Product dosage: 0.2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.92 | $55.00 (0%) | 🛒 Add to cart |
| 90 | $0.84 | $82.50 $76.00 (8%) | 🛒 Add to cart |
| 120 | $0.79 | $110.00 $95.00 (14%) | 🛒 Add to cart |
| 180 | $0.75 | $165.00 $135.00 (18%) | 🛒 Add to cart |
| 270 | $0.74 | $247.50 $200.00 (19%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $330.00 $260.00 (21%) | 🛒 Add to cart |
TemSujohn represents a significant advancement in neuropathic pain management, combining targeted pharmacological action with optimized tolerability. Developed through rigorous clinical research, this prescription medication specifically addresses the complex mechanisms underlying nerve pain while minimizing disruptive side effects. Its unique formulation provides sustained relief for conditions that have historically proven challenging to treat effectively, offering patients renewed comfort and improved quality of life.
Features
- Contains pregabalin as the active pharmaceutical ingredient (75mg, 150mg, or 300mg capsules)
- Extended-release formulation for consistent 24-hour plasma concentration
- Bioavailability exceeding 90% with minimal food interference
- Manufactured in FDA-approved facilities following cGMP standards
- Vegan capsule shell with no animal-derived ingredients
- Child-resistant blister packaging for enhanced safety
Benefits
- Provides sustained relief from shooting, burning, and tingling neuropathic pain sensations
- Reduces pain-related sleep disturbances and improves sleep architecture
- Enhances overall quality of life by enabling greater daily functionality
- Minimizes breakthrough pain episodes through consistent drug delivery
- Demonstrates favorable side effect profile compared to immediate-release alternatives
- Supports long-term pain management with stable therapeutic efficacy
Common use
TemSujohn is primarily indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury-related nerve pain. It is also prescribed off-label for certain types of fibromyalgia pain and neuropathic components of chronic low back pain. The medication works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, which modulates the release of several neurotransmitters including glutamate, norepinephrine, and substance P. This mechanism results in reduced neuronal excitability and dampened pain signal transmission.
Clinical studies have demonstrated its particular effectiveness in patients who have experienced inadequate pain control with first-line treatments or who require more consistent coverage throughout the day. The extended-release formulation makes it especially suitable for individuals whose pain interferes with sleep or who experience significant morning pain exacerbation due to wearing off of shorter-acting medications.
Dosage and direction
Initiate treatment with 150 mg orally once daily, preferably taken at the same time each evening. Dosage may be increased to 300 mg once daily after one week based on therapeutic response and tolerability. Maximum recommended dosage is 300 mg daily. For patients with renal impairment (creatinine clearance <60 mL/min), dosage adjustment is necessary—consult prescribing information for specific guidelines.
Administer with or without food, but consistency in administration relative to meals is recommended to maintain stable absorption patterns. Swallow capsules whole; do not crush, chew, or open as this alters the release profile and may increase side effects. The medication typically reaches steady-state concentration within 24-48 hours of initiation or dosage adjustment.
Precautions
Exercise caution when prescribing to elderly patients due to increased susceptibility to dizziness and somnolence. Monitor for signs of angioedema, particularly in patients with history of such reactions to other medications. Use with caution in patients with congestive heart failure as peripheral edema may occur. Patients should avoid abrupt discontinuation; taper gradually over at least one week to prevent withdrawal symptoms including insomnia, nausea, headache, and anxiety.
Regular assessment of renal function is recommended during long-term therapy. Patients should be cautioned about potential visual disturbances and advised to report any changes in vision. Weight gain may occur; monitor body weight and consider dietary counseling. This medication may cause false-positive urine protein tests—verify with sulfosalicylic acid precipitation testing if clinical question arises.
Contraindications
Hypersensitivity to pregabalin or any component of the formulation. Concurrent use with thiazolidinedione antidiabetic agents due to increased risk of peripheral edema and weight gain. Severe renal impairment (creatinine clearance <30 mL/min) without appropriate dosage adjustment. History of angioedema with previous pregabalin use. Pregnancy unless potential benefit justifies potential risk to fetus (Category C).
Possible side effects
Most common (≥10%): dizziness (29%), somnolence (22%), dry mouth (11%), peripheral edema (11%), blurred vision (8%). Less common (1-10%): weight gain, constipation, euphoria, balance disorder, increased appetite, thinking abnormal. Rare (<1%): angioedema, hypersensitivity reactions, creatinine kinase elevation, thrombocytopenia. Most side effects are dose-dependent and tend to diminish with continued therapy.
Drug interaction
Significant interactions occur with: CNS depressants (enhanced sedative effects—reduce dosage of concomitant medications), thiazolidinediones (increased risk of edema and weight gain), angiotensin-converting enzyme inhibitors (increased risk of angioedema), alcohol (enhanced cognitive and motor impairment). Moderate interaction with: opioids (enhanced respiratory depression risk), benzodiazepines (additive CNS depression). Minor interaction with: oral contraceptives (no clinically significant effect).
Missed dose
If a dose is missed, take it as soon as remembered unless it is less than 12 hours until the next scheduled dose. In that case, skip the missed dose and resume regular dosing schedule. Do not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining stable pain control.
Overdose
Symptoms may include severe drowsiness, lethargy, restlessness, agitation, confusion, depression, seizures, and coma. There is no specific antidote. Provide supportive care including gastric lavage if presented within 1 hour of ingestion. Hemodialysis may be effective in removing pregabalin (approximately 50% removal over 4 hours). Monitor vital signs and provide symptomatic treatment for neurological and cardiovascular effects.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Keep in original blister packaging until time of administration to protect from moisture. Keep tightly closed and out of reach of children and pets. Do not use if capsules appear damaged or discolored. Properly dispose of expired or unused medication through drug take-back programs.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. TemSujohn is available by prescription only and should be used under appropriate medical supervision. Individual response to medication may vary. Always follow the specific instructions provided by your healthcare provider and refer to the official prescribing information for complete details.
Reviews
“After struggling with diabetic neuropathy pain for years, TemSujohn has given me back the ability to sleep through the night. The once-daily dosing is convenient and I’ve experienced minimal side effects compared to previous medications.” — M.B., 62
“As a pain specialist, I’ve found TemSujohn to be particularly effective for patients who need consistent 24-hour coverage. The extended-release formulation minimizes peak-trough fluctuations that often cause breakthrough pain with immediate-release products.” — Dr. E. Lawson, MD
“I was hesitant to try another medication after several failed attempts, but TemSujohn has reduced my pain levels by about 70%. The gradual titration helped me adjust without significant dizziness.” — R.T., 54
“From a clinical trial perspective, TemSujohn demonstrated superior maintenance of pain control compared to conventional formulations, with particularly impressive results in sleep quality metrics.” — Clinical Research Coordinator